Company Name: bluebird bio, Inc.
bluebird bio, Inc. is a clinical-stage biotechnology company. The company is engaged in developing gene therapies for severe genetic and rare diseases. The company’s pipeline includes treatment candidates for childhood cerebral adrenoleukodystrophy (CCALD), beta-thalassemia major and severe sickle cell disease. The company also develops T cell-based cancer immunotherapies.
Ticker Symbol: BLUE (NASDAQ)
Company Website: www.bluebirdbio.com
Headquarters: Cambridge, Massachusetts